ÃÖ¹Îö
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ºÎÀÎÁ¾¾çÇÐ,·Îº¿¼ö¼ú,ÇÏÀÌÆå(HIPEC)
Á÷
ˤ
: ºÎ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
12
±¹³»
Re: Endometrial cancer occurrence five years after breast cancer in BRCA2 mutation patient
11
ÇØ¿Ü
Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis
10
ÇØ¿Ü
Dysregulated MicroRNA Expression in Adenocarcinoma of the Uterine Cervix: Clinical Impact of miR-363-3p
9
ÇØ¿Ü
Re: Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: A systemic review
8
ÇØ¿Ü
Fertility-sparing management combined with photodynamic therapy for endometrial stromal sarcoma: a case report
7
ÇØ¿Ü
Fertility Preservation by photodynamic therapy combined with conization in young patients with early stage cervical cancer: A Pilot Study
6
±¹³»
Preoperative Thrombocytosis Is an Independent Poor Prognostic Factor in Patients with Epithelial Ovarian Cancer
5
ÇØ¿Ü
Photodynamic Therapy for Management of Cervical Intraepithelial Neoplasia II and III in Young Patients and Obstetric Outcomes
4
ÇØ¿Ü
Fertility Preservation via Photodynamic Therapy in Young Patients With Early-Stage Uterine Endometrial Cancer A Long-term Follow-up Study
3
±¹³»
Comparison of postoperative radiotherapy versus postoperative paclitaxel and platinum chemotherapy in uterine endometrial carcinoma
1
2
3
4
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729